318 related articles for article (PubMed ID: 32427409)
1. Targeted next generation sequencing of MLH1-deficient, MLH1 promoter hypermethylated, and BRAF/RAS-wild-type colorectal adenocarcinomas is effective in detecting tumors with actionable oncogenic gene fusions.
Vaňková B; Vaněček T; Ptáková N; Hájková V; Dušek M; Michal M; Švajdler P; Daum O; Daumová M; Michal M; Mezencev R; Švajdler M
Genes Chromosomes Cancer; 2020 Oct; 59(10):562-568. PubMed ID: 32427409
[TBL] [Abstract][Full Text] [Related]
2. Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions.
Cocco E; Benhamida J; Middha S; Zehir A; Mullaney K; Shia J; Yaeger R; Zhang L; Wong D; Villafania L; Nafa K; Scaltriti M; Drilon A; Saltz L; Schram AM; Stadler ZK; Hyman DM; Benayed R; Ladanyi M; Hechtman JF
Cancer Res; 2019 Mar; 79(6):1047-1053. PubMed ID: 30643016
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of oncogenic fusions in mismatch repair deficient colorectal carcinomas by sequential DNA and RNA next generation sequencing.
Wang J; Li R; Li J; Yi Y; Liu X; Chen J; Zhang H; Lu J; Li C; Wu H; Liang Z
J Transl Med; 2021 Oct; 19(1):433. PubMed ID: 34657620
[TBL] [Abstract][Full Text] [Related]
4. Gene fusions and oncogenic mutations in MLH1 deficient and BRAFV600E wild-type colorectal cancers.
Ukkola I; Nummela P; Kero M; Tammio H; Tuominen J; Kairisto V; Kallajoki M; Haglund C; Peltomäki P; Kytölä S; Ristimäki A
Virchows Arch; 2022 Apr; 480(4):807-817. PubMed ID: 35237889
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcinoma with hypermethylated MLH1 and wild-type BRAF and KRAS.
Wang J; Yi Y; Xiao Y; Dong L; Liang L; Teng L; Ying JM; Lu T; Liu Y; Guan Y; Pang J; Zhou L; Lu J; Zhang Z; Liu X; Liang X; Zeng X; Yi X; Zhou W; Xia X; Yang L; Zhang J; Kopetz S; Futreal PA; Wu H; Liang Z
Mod Pathol; 2019 Jul; 32(7):1053-1064. PubMed ID: 30723297
[TBL] [Abstract][Full Text] [Related]
6. MSI-High RAS-BRAF wild-type colorectal adenocarcinomas with MLH1 loss have a high frequency of targetable oncogenic gene fusions whose diagnoses are feasible using methods easy-to-implement in pathology laboratories.
Bocciarelli C; Caumont C; Samaison L; Cariou M; Aline-Fardin A; Doucet L; Roudié J; Terris B; Merlio JP; Marcorelles P; Cappellen D; Uguen A
Hum Pathol; 2021 Aug; 114():99-109. PubMed ID: 34019865
[TBL] [Abstract][Full Text] [Related]
7. MLH1-deficient Colorectal Carcinoma With Wild-type BRAF and MLH1 Promoter Hypermethylation Harbor KRAS Mutations and Arise From Conventional Adenomas.
Farchoukh L; Kuan SF; Dudley B; Brand R; Nikiforova M; Pai RK
Am J Surg Pathol; 2016 Oct; 40(10):1390-9. PubMed ID: 27438990
[TBL] [Abstract][Full Text] [Related]
8. NTRK gene rearrangements are highly enriched in MLH1/PMS2 deficient, BRAF wild-type colorectal carcinomas-a study of 4569 cases.
Chou A; Fraser T; Ahadi M; Fuchs T; Sioson L; Clarkson A; Sheen A; Singh N; Corless CL; Gill AJ
Mod Pathol; 2020 May; 33(5):924-932. PubMed ID: 31792356
[TBL] [Abstract][Full Text] [Related]
9. ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.
Aisner DL; Nguyen TT; Paskulin DD; Le AT; Haney J; Schulte N; Chionh F; Hardingham J; Mariadason J; Tebbutt N; Doebele RC; Weickhardt AJ; Varella-Garcia M
Mol Cancer Res; 2014 Jan; 12(1):111-8. PubMed ID: 24296758
[TBL] [Abstract][Full Text] [Related]
10. Next-generation sequencing reveals heterogeneous genetic alterations in key signaling pathways of mismatch repair deficient colorectal carcinomas.
Wang J; Li R; He Y; Yi Y; Wu H; Liang Z
Mod Pathol; 2020 Dec; 33(12):2591-2601. PubMed ID: 32620917
[TBL] [Abstract][Full Text] [Related]
11. Amplicon-based NGS test for assessing MLH1 promoter methylation and its correlation with BRAF mutation in colorectal cancer patients.
da Silva SIO; Domingos TA; Kupper BEC; De Brot L; Aguiar Junior S; Carraro DM; Torrezan GT
Exp Mol Pathol; 2023 Apr; 130():104855. PubMed ID: 36736685
[TBL] [Abstract][Full Text] [Related]
12.
Mulkidjan RS; Saitova ES; Preobrazhenskaya EV; Asadulaeva KA; Bubnov MG; Otradnova EA; Terina DM; Shulga SS; Martynenko DE; Semina MV; Belogubova EV; Tiurin VI; Amankwah PS; Martianov AS; Imyanitov EN
Int J Mol Sci; 2023 Sep; 24(17):. PubMed ID: 37686416
[TBL] [Abstract][Full Text] [Related]
13. Double somatic mutations in mismatch repair genes are frequent in colorectal cancer after Hodgkin's lymphoma treatment.
Rigter LS; Snaebjornsson P; Rosenberg EH; Atmodimedjo PN; Aleman BM; Ten Hoeve J; Geurts-Giele WR; ; van Ravesteyn TW; Hoeksel J; Meijer GA; Te Riele H; van Leeuwen FE; Dinjens WN; van Leerdam ME
Gut; 2018 Mar; 67(3):447-455. PubMed ID: 29439113
[TBL] [Abstract][Full Text] [Related]
14. Rational testing for gene fusion in colorectal cancer: MSI and RAS-BRAF wild-type metastatic colorectal cancer as target population for systematic screening.
Delaye M; Ibadioune S; Julié C; Marin C; Peschaud F; Lupinacci R; Vacher S; Ahmanache L; Antonio S; Schnitzler A; Buecher B; Mariani P; Allory Y; Grati OT; Emile JF; Neuzillet C; Bièche I
Eur J Cancer; 2022 Jul; 170():85-90. PubMed ID: 35598360
[TBL] [Abstract][Full Text] [Related]
15. MGMT and MLH1 promoter methylation versus APC, KRAS and BRAF gene mutations in colorectal cancer: indications for distinct pathways and sequence of events.
de Vogel S; Weijenberg MP; Herman JG; Wouters KA; de Goeij AF; van den Brandt PA; de Bruïne AP; van Engeland M
Ann Oncol; 2009 Jul; 20(7):1216-22. PubMed ID: 19164452
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target.
Yakirevich E; Resnick MB; Mangray S; Wheeler M; Jackson CL; Lombardo KA; Lee J; Kim KM; Gill AJ; Wang K; Gowen K; Sun J; Miller VA; Stephens PJ; Ali SM; Ross JS; Safran H
Clin Cancer Res; 2016 Aug; 22(15):3831-40. PubMed ID: 26933125
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer.
Hampel H; Pearlman R; Beightol M; Zhao W; Jones D; Frankel WL; Goodfellow PJ; Yilmaz A; Miller K; Bacher J; Jacobson A; Paskett E; Shields PG; Goldberg RM; de la Chapelle A; Shirts BH; Pritchard CC;
JAMA Oncol; 2018 Jun; 4(6):806-813. PubMed ID: 29596542
[TBL] [Abstract][Full Text] [Related]
18. Distinction of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through quantification of MLH1 methylation by real-time PCR.
Bettstetter M; Dechant S; Ruemmele P; Grabowski M; Keller G; Holinski-Feder E; Hartmann A; Hofstaedter F; Dietmaier W
Clin Cancer Res; 2007 Jun; 13(11):3221-8. PubMed ID: 17545526
[TBL] [Abstract][Full Text] [Related]
19. Cell block-based RNA next generation sequencing for detection of gene fusions in lung adenocarcinoma: An institutional experience.
Wei S; Talarchek JN; Huang M; Gong Y; Du F; Ehya H; Flieder DB; Patchefsky AS; Wasik MA; Pei J
Cytopathology; 2023 Jan; 34(1):28-34. PubMed ID: 36062384
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological and molecular characterization of deficient mismatch repair colorectal cancer.
Yamada A; Yamamoto Y; Minamiguchi S; Kamada M; Sunami T; Ohashi S; Seno H; Kawada K; Muto M
Hum Pathol; 2022 Dec; 130():1-9. PubMed ID: 36150551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
